Niaid VRC FY26-27 operational task order
Active Awarded Last action
- Contract number
- 75N91025F00014
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $87,806,507
Award facts
- Contract value 100% obligated
- $87,806,507.00 Current and potential, with all options
- Completion date 57% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Funding Only Action | $707,088 | |
| Exercise an Option | $44,176,296 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $36,643,441 | |
| Original award | $6,279,682 |
About this award
The National Institute of Allergy and Infectious Diseases issued a delivery order to Leidos Biomedical Research Inc. on August 31, 2025, with a ceiling value of $87.8 million under its master indefinite delivery contract for operational biomedical research and facility support services through August 30, 2027.
Place of performance is Frederick, Maryland. The order is priced on a cost-plus-fixed-fee basis with no set-aside. Leidos Biomedical Research operates the Frederick National Laboratory for Cancer Research campus and delivers infectious disease research execution, clinical trial support, facilities infrastructure management, and specialized biomedical manufacturing capability spanning monoclonal antibodies, gene therapy vectors, vaccine platform development, and chemistry, manufacturing, and controls support for therapeutic candidates.
Service Contract Inventory data for FY2025 shows $3 million invoiced against 1.6 FTEs, with all work self-performed by the prime and no subcontractor engagement reported in that fiscal year. Government-paid hourly rates on Leidos Biomedical Research's broader SCI-reportable contract portfolio range from $70.79 to $1,379.73 per hour, reflecting entry-level through senior specialized research roles. The vendor maintains a stable workforce of approximately 1,830 FTEs across recent years and engages a broad subcontractor network for roughly one-third of total contractor hours on other active awards, including academic institutions and specialized equipment manufacturers.
Quick answers
Who was awarded contract 75N91025F00014?
75N91025F00014 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on August 31, 2025.
How much is contract 75N91025F00014 worth?
The government has obligated $87,806,507 on 75N91025F00014.
Which agency awarded contract 75N91025F00014?
National Cancer Institute (National Institutes of Health) awarded 75N91025F00014, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91025F00014 an order under another contract?
Yes. 75N91025F00014 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91025F00014 competed?
The extent of competition for 75N91025F00014 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award